12/2
08:01 am
mynz
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
Medium
Report
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
11/18
01:18 pm
mynz
Mainz Biomed (NASDAQ:MYNZ) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mainz Biomed (NASDAQ:MYNZ) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
08:42 am
mynz
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America [Yahoo! Finance]
Low
Report
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America [Yahoo! Finance]
11/18
08:01 am
mynz
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
High
Report
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
11/12
01:27 pm
mynz
Mainz Biomed (NASDAQ:MYNZ) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Mainz Biomed (NASDAQ:MYNZ) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
08:01 am
mynz
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
Medium
Report
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
11/10
08:40 am
mynz
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) [Yahoo! Finance]
Neutral
Report
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) [Yahoo! Finance]
11/10
08:01 am
mynz
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
Neutral
Report
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
10/15
09:01 am
mynz
Mainz Biomed to Attend 2025 Maxim Growth Summit
Medium
Report
Mainz Biomed to Attend 2025 Maxim Growth Summit
10/8
09:00 am
mynz
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Medium
Report
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
10/3
03:40 pm
mynz
Mainz Biomed (NASDAQ:MYNZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mainz Biomed (NASDAQ:MYNZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
08:01 am
mynz
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
Low
Report
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
9/23
08:01 am
mynz
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Medium
Report
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland